Xinlitai announced that the company and its wholly-owned subsidiary have received an acceptance notice from the State Drug Administration, and the clinical trial application for injectable SAL012, a class 1 new drug developed independently for the treatment of advanced solid tumors, has been accepted. The acceptance number is CXSL2600858. If no negative or questionable opinions have been received within 60 days from the date of acceptance, clinical trials may be carried out in accordance with the submitted plan.

Xinlitai announced that the company and its wholly-owned subsidiary have received an acceptance notice from the State Drug Administration, and the clinical trial application for injectable SAL012, a class 1 new drug developed independently for the treatment of advanced solid tumors, has been accepted. The acceptance number is CXSL2600858. If no negative or questionable opinions have been received within 60 days from the date of acceptance, clinical trials may be carried out in accordance with the submitted plan.